Cathepsin S inhibition combines control of systemic and peripheral pathomechanisms of autoimmune tissue injury

Scientific Reports

Volumn 7, Issue 1, 2017, Pages

  Tato, Maia ^a   Kumar, Santhosh V ^a   Liu, Yajuan ^a,b   Mulay, Shrikant R ^a   Moll, Solange ^c   Popper, Bastian ^d   Eberhard, Jonathan N ^a   Thomasova, Dana ^a   Rufer, Arne Christian ^e   Gruner, Sabine ^e   Haap, Wolfgang ^e   Hartmann, Guido ^e   Anders, Hans Joachim ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^d UNIVERSITY OF MUNICH   (Germany)

^e F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CATHEPSIN; CATHEPSIN S; ENZYME INHIBITOR; F2RL1 PROTEIN, MOUSE; PROTEINASE ACTIVATED RECEPTOR 2;

ANIMAL; ANTAGONISTS AND INHIBITORS; AUTOIMMUNE DISEASE; AUTOIMMUNITY; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECT; ENDOTHELIUM CELL; FEMALE; GENETICS; GLOMERULUS; IMMUNOLOGY; LUPUS ERYTHEMATOSUS NEPHRITIS; METABOLISM; MONOCYTE; MOUSE; MURPHY ROTHS LARGE LYMPHOPROLIFERATIVE MOUSE; NEUTROPHIL; PATHOLOGY;

ANIMALS; AUTOIMMUNE DISEASES; AUTOIMMUNITY; CATHEPSINS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; ENZYME INHIBITORS; FEMALE; KIDNEY GLOMERULUS; LUPUS NEPHRITIS; MICE; MICE, INBRED MRL LPR; MONOCYTES; NEUTROPHILS; RECEPTOR, PAR-2;

EID: 85020448960     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-017-01894-y     Document Type: Article

References (49)

1. Goodnow, C. C. Multistep pathogenesis of autoimmune disease. Cell 130, 25-35, doi:10.1016/j.cell.2007.06.033 (2007).
2. Hogan, J., Avasare, R. & Radhakrishnan, J. Is newer safer? Adverse events associated with first-line therapies for ANCA-Associated vasculitis and lupus nephritis. Clinical journal of the American Society of Nephrology: CJASN 9, 1657-1667, doi:10.2215/CJN.01600214 (2014).
3. Aringer, M. et al. Adverse events and efficacy of TNF-Alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients. Rheumatology 48, 1451-1454, doi:10.1093/rheumatology/kep270 (2009).
4. Merrill, J. T. et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis and rheumatism 62, 222-233, doi:10.1002/art.27233 (2010).
5. Roche, P. A. & Furuta, K. The ins and outs of MHC class II-mediated antigen processing and presentation. Nature reviews. Immunology 15, 203-216, doi:10.1038/nri3818 (2015).
6. Gupta, S., Singh, R. K., Dastidar, S. & Ray, A. Cysteine cathepsin S as an immunomodulatory target: present and future trends. Expert opinion on therapeutic targets 12, 291-299, doi:10.1517/14728222.12.3.291 (2008).
7. Blum, J. S. & Cresswell, P. Role for intracellular proteases in the processing and transport of class II HLA antigens. Proceedings of the National Academy of Sciences 85, 3975-3979, doi:10.1073/pnas.85.11.3975 (1988).
8. Driessen, C. et al. Cathepsin S controls the trafficking and maturation of MHC class II molecules in dendritic cells. The Journal of cell biology 147, 775-790, doi:10.1083/jcb.147.4.775 (1999).
9. Germain, R. N. MHC-dependent antigen processing and peptide presentation: Providing ligands for T lymphocyte activation. Cell 76, 287-299, doi:10.1016/0092-8674(94)90336-0 (1994).
10. Riese, R. J. et al. Cathepsin S activity regulates antigen presentation and immunity. The Journal of clinical investigation 101, 2351-2363, doi:10.1172/JCI1158 (1998).
11. Riese, R. J. et al. Essential role for cathepsin S in MHC class II-Associated invariant chain processing and peptide loading. Immunity 4, 357-366, doi:10.1016/S1074-7613(00)80249-6 (1996).
12. Roche, P. A., Marks, M. S. & Cresswell, P. J. Formation of a nine-subunit complex by HLA class II glycoproteins and the invariant chain. Nature 354, 392-394, doi:10.1038/354392a0 (1991).
13. Shi, G. P., Munger, J. S., Meara, J. P., Rich, D. H. & Chapman, H. A. Molecular cloning and expression of human alveolar macrophage cathepsin S, an elastinolytic cysteine protease. The Journal of biological chemistry 267, 7258-7262 (1992).
14. Stoeckle, C. et al. Cathepsin S dominates autoantigen processing in human thymic dendritic cells. Journal of autoimmunity 38, 332-343, doi:10.1016/j.jaut.2012.02.003 (2012).
15. Baugh, M. et al. Therapeutic dosing of an orally active, selective cathepsin S inhibitor suppresses disease in models of autoimmunity. Journal of autoimmunity 36, 201-209, doi:10.1016/j.jaut.2011.01.003 (2011).
16. Saegusa, K. et al. Cathepsin S inhibitor prevents autoantigen presentation and autoimmunity. The Journal of clinical investigation 110, 361-369, doi:10.1172/JCI14682 (2002).
17. Bernard, N. J. Connective tissue diseases. Inhibiting cathepsin S to treat SLE and lupus nephritis. Nature reviews. Rheumatology 10, 66-66, doi:10.1038/nrrheum.2013.207 (2014).
18. Elmariah, S. B., Reddy, V. B. & Lerner, E. A. Cathepsin S signals via PAR2 and generates a novel tethered ligand receptor agonist. PloS one 9, e99702, doi:10.1371/journal.pone.0099702 (2014).
19. Kumar, S. V. et al. Neutrophil Extracellular Trap-Related Extracellular Histones Cause Vascular Necrosis in Severe GN. Journal of the American Society of Nephrology: JASN 26, 2399-2413, doi:10.1681/ASN.2014070673 (2015).
20. Zhao, P. et al. Cathepsin S causes inflammatory pain via biased agonism of PAR2 and TRPV4. The Journal of biological chemistry 289, 27215-27234, doi:10.1074/jbc.M114.599712 (2014).
21. Kumar Vr, S. et al. Cathepsin S Cleavage of Protease-Activated Receptor-2 on Endothelial Cells Promotes Microvascular Diabetes Complications. Journal of the American Society of Nephrology: JASN 27, 1635-1649, doi:10.1681/ASN.2015020208 (2016).
22. Lech, M. et al. IRF4 Deficiency Abrogates Lupus Nephritis Despite Enhancing Systemic Cytokine Production. Journal of the American Society of Nephrology 22, 1443-1452, doi:10.1681/asn.2010121260 (2011).
23. Rupanagudi, K. V. et al. Cathepsin S inhibition suppresses systemic lupus erythematosus and lupus nephritis because cathepsin S is essential for MHC class II-mediated CD4 T cell and B cell priming. Annals of the rheumatic diseases 74, 452-463, doi:10.1136/annrheumdis-2013-203717 (2015).
24. Jonsson, C. A., Svensson, L. & Carlsten, H. Beneficial effect of the inosine monophosphate dehydrogenase inhibitor mycophenolate mofetil on survival and severity of glomerulonephritis in systemic lupus erythematosus (SLE)-prone MRLlpr/lpr mice. Clinical and experimental immunology 116, 534-541, doi:10.1046/j.1365-2249.1999.00901.x (1999).
25. Lui, S. L. et al. Effect of mycophenolate mofetil on severity of nephritis and nitric oxide production in lupus-prone MRL/lpr mice. Lupus 11, 411-418, doi:10.1191/0961203302lu214oa (2002).
26. Van Bruggen, M. C., Walgreen, B., Rijke, T. P. & Berden, J. H. Attenuation of murine lupus nephritis by mycophenolate mofetil. Journal of the American Society of Nephrology: JASN 9, 1407-1415 (1998).
27. Boes, M. Role of natural and immune IgM antibodies in immune responses. Molecular immunology 37, 1141-1149, doi:10.1016/S0161-5890(01)00025-6 (2000).
28. Gross, O. et al. Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy. Kidney international 81, 494-501, doi:10.1038/ki.2011.407 (2012).
29. Bosch, X. Systemic lupus erythematosus and the neutrophil. The New England journal of medicine 365, 758-760, doi:10.1056/NEJMcibr1107085 (2011).
30. Bethunaickan, R. et al. A unique hybrid renal mononuclear phagocyte activation phenotype in murine systemic lupus erythematosus nephritis. Journal of immunology 186, 4994-5003, doi:10.4049/jimmunol.1003010 (2011).
31. Allam, R. & Anders, H. J. The role of innate immunity in autoimmune tissue injury. Current opinion in rheumatology 20, 538-544, doi:10.1097/BOR.0b013e3283025ed4 (2008).
32. Anders, H. J. et al. Late onset of treatment with a chemokine receptor CCR1 antagonist prevents progression of lupus nephritis in MRL-Fas(lpr) mice. Journal of the American Society of Nephrology: JASN 15, 1504-1513, doi:10.1097/01.ASN.0000130082.67775.60 (2004).
33. Kurts, C., Panzer, U., Anders, H. J. & Rees, A. J. The immune system and kidney disease: basic concepts and clinical implications. Nature reviews. Immunology 13, 738-753, doi:10.1038/nri3523 (2013).
34. Vielhauer, V., Kulkarni, O., Reichel, C. A. & Anders, H. J. Targeting the recruitment of monocytes and macrophages in renal disease. Seminars in nephrology 30, 318-333, doi:10.1016/j.semnephrol.2010.03.006 (2010).
35. Ruge, T., Sodergren, A., Wallberg-Jonsson, S., Larsson, A. & Arnlov, J. Circulating plasma levels of cathepsin S and L are not associated with disease severity in patients with rheumatoid arthritis. Scandinavian journal of rheumatology 43, 371-373, doi:10.31 09/03009742.2014.882979 (2014).
36. Zhang, T. P. et al. Plasma levels of adipokines in systemic lupus erythematosus patients. Cytokine 86, 15-20, doi:10.1016/j. cyto.2016.07.008 (2016).
37. Arnlov, J. Cathepsin S as a biomarker: where are we now and what are the future challenges? Biomarkers in medicine 6, 9-11, doi:10.2217/bmm.11.102 (2012).
38. Jobs, E. et al. Association between serum cathepsin S and mortality in older adults. Jama 306, 1113-1121, doi:10.1001/jama.2011.1246 (2011).
39. Manger, K. et al. Definition of risk factors for death, end stage renal disease, and thromboembolic events in a monocentric cohort of 338 patients with systemic lupus erythematosus. Annals of the rheumatic diseases 61, 1065-1070, doi:10.1136/ard.61.12.1065 (2002).
40. Copeland, R. A. Tight binding inhibitors. 2nd edn, 305-317 (Wiley-VCH, Inc., 2000).
41. Patole, P. S. et al. Coactivation of Toll-like receptor-3 and-7 in immune complex glomerulonephritis. Journal of autoimmunity 29, 52-59, doi:10.1016/j.jaut.2007.04.004 (2007).
42. Austin, H. A. 3rd, Muenz, L. R., Joyce, K. M., Antonovych, T. T. & Balow, J. E. Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome. Kidney international 25, 689-695, doi:10.1038/ki.1984.75 (1984).
43. Allam, R. et al. Viral 5?-triphosphate RNA and non-CpG DNA aggravate autoimmunity and lupus nephritis via distinct TLRindependent immune responses. European journal of immunology 38, 3487-3498, doi:10.1002/eji.200838604 (2008).
44. Pawar, R. D. et al. Bacterial lipopeptide triggers massive albuminuria in murine lupus nephritis by activating Toll-like receptor 2 at the glomerular filtration barrier. Immunology 128, e206-221, doi:10.1111/j.1365-2567.2008.02948.x (2009).
45. Kulkarni, O. et al. Spiegelmer Inhibition of CCL2/MCP-1 Ameliorates Lupus Nephritis in MRL-(Fas)lpr Mice. Journal of the American Society of Nephrology 18, 2350-2358, doi:10.1681/asn.2006121348 (2007).
46. Weening, J. J. et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Journal of the American Society of Nephrology: JASN 15, 241-250, doi:10.1097/01.ASN.0000108969.21691.5D (2004).
47. Lech, M. & Anders, H. J. Expression profiling by real-time quantitative polymerase chain reaction (RT-qPCR). Methods in molecular biology 1169, 133-142, doi:10.1007/978-1-4939-0882-0-13 (2014).
48. Lech, M. et al. Quantitative expression of C-type lectin receptors in humans and mice. Int J Mol Sci 13, 10113-10131, doi:10.3390/ijms130810113 (2012).
49. Dennis J. Murphy, Determination of accurate KI values for tight-binding enzyme inhibitors: an in silico study of experimental error and assay design. Analytical Biochemistry 327(1), 61-67 (2004).